Business
Oculis to Present its Innovative Late-Stage Pipeline Candidates at Upcoming Ophthalmology Conferences
ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on
About this update from Oculis Holding Ag
[{"type":"text","content":"ZUG, Switzerland, May 01, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / ICX: OCS.IC) (“Oculis”), a global biopharmaceutical company focused on innovations addressing ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced upcoming presentations highlighting its innovative late-stage pipeline at Eyecelerator 2025, the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting and the Retina World Congress (RWC). The presentation of the DME AWARE Delphi Study interim results will highlight key areas of consensus on unmet needs in DME patient management among leading global experts. Further insights from Stage 1 of the Phase 3 DIAMOND program reinforcing the efficacy and safety profile of OCS-01 eye drops for DME will also be shared. OCS-01 is being developed to be the first non-invasive treatment for DME, addressing key unmet needs for earlier treatment intervention and for inadequate responders to the current standard of care. Data from the Phase 2b RELIEF trial investigating Licaminlimab (OCS-02) in signs of DED will be presented following positive and consistent results from phase 2 trials in symptoms. The genetic biomarker, previously identified, to predict response to Licaminlimab, enables the first genotype-based development plan to drive a personalized approach in dry eye disease (DED). Licaminlimab is being developed to transform the treatment paradigm in DED, currently driven by trial and error, and address unmet medical needs for this multifactorial disease with a dissatisfied patient population. Details of the presentations are as follows: Eyecelerator 2025 Company showcases – Retina: TKI and Drug DeliveryPresenter: Sharon Klier, M.D., Chief Development OfficerDate/Time: Friday, May 2, 2025, 1:30 PM – 3:00 PM MST ARVO Annual Meeting 2025 Interim results of the DME AWARE Delphi Study on unmet needs in DME patient managementPresenter: Anat Loewenstein, M.D., MHASession: #261Presentation: #2587Posterboard: #B0300Date/Time: Monday, May 5, 2025, 3:00 PM – 4:45 PM MSTBCVA and CST Improvement over 12 weeks with OCS-01 Eye Drops in DME from DIAMOND Stage 1 trialPresenter: Carl Danzig, M.D.Session: 401Presentation: #4011Location: Room #255ABCDate/Time: Wednesday, May 7, 2025, 10:15 AM – 12:00 PM MSTLicaminlimab in the treatment of dry eye diseasePresenter: Anat G...